Racial differences in initial presentation, early treatment, and 1-year outcomes of pediatric Crohn's disease: results from the ImproveCareNow network
Dotson JL, Cho M, Bricker J, Kappelman M, Chisolm D, Tomer G, Crandall W. Racial differences in initial presentation, early treatment, and 1-year outcomes of pediatric Crohn's disease: results from the ImproveCareNow network. Inflamm Bowel Dis 2016;22:doi: 10.1097/01
Feasibility of a mobile personalized learning system for assessing daily IBD symptoms and quality of life
Adler J, Saeed S, Thakkar S, Eslick I, Margolis P, Provost L, Kaplan H. Feasibility of a mobile personalized learning system for assessing daily IBD symptoms and quality of life. Inflamm Bowel Dis 2016;22:doi: 10.1097/01
The use of concomitant immunomodulators with adalimumab therapy in pediatric Crohn's disease
Benkov JK, Russell GH, Samson C, Steiner S, King E, Pratt J, Eichner S, Colletti RB. The use of concomitant immunomodulators with adalimumab therapy in pediatric Crohn's disease. Gastroenterol 2016;150(4):S588
The use of concomitant immunomodulators with adalimumab therapy in pediatric Crohn's disease
Benkov JK, Russell GH, Samson C, Steiner S, King E, Pratt J, Eichner S, Colletti RB. The use of concomitant immunomodulators with adalimumab therapy in pediatric Crohn's disease. J Pediatr Gastro Nutr 2016;62:77
Prevention of perianal disease among pediatric patients with Crohn's disease in a pediatric inflammatory bowel disease quality improvement collaborative
Adler J, Dong S, Dombkowski K. Prevention of perianal disease among pediatric patients with Crohn's disease in a pediatric inflammatory bowel disease quality improvement collaborative. J of Pediatr Gastro 2016;63:S364
Efficacy and safety of co-therapy of biologics and methotrexate in a pediatric inflammatory bowel disease (pIBD) cohort: a single centre experience
Lozinsky A, Kiparissi F, Huggett B, Chadokufa S, Sider S, Acton N, Baycheva M, Shah N. Efficacy and safety of co-therapy of biologics and methotrexate in a pediatric inflammatory bowel disease (pIBD) cohort: a single centre experience. J of Pediatr Gastro 2016;63(S2):S210-211